Previous 10 | Next 10 |
Novocure (NASDAQ: NVCR) disappointed investors with its second-quarter results announced on July 29. However, the company could have better news on the way. In this Motley Fool Live video recorded on Aug. 4 , Motley Fool contributors Keith Speights and Brian Orelli discuss w...
Shares of Novocure (NASDAQ: NVCR) slid this week in response to a disappointing second-quarter earnings report. Investors aren't happy about the slower-than-anticipated rollout of the company's Tumor Treating Fields, or TTF, therapy. The healthcare stock finished the week down 18.7%...
The following slide deck was published by NovoCure Limited in conjunction with their 2021 Q2 earnings call. For further details see: NovoCure Limited 2021 Q2 - Results - Earnings Call Presentation
Quarterly earnings aren't providing much of a cure for Novocure (NASDAQ: NVCR) . The company, which concentrates on novel cancer-fighting solutions, saw its stock dive by almost 10% on Thursday following the publication of its latest set of results. In Q2, Novocure took in $...
Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2021 Earnings Call Jul 29, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2021 Earnings Call Transcript
NovoCure Limited (NVCR) Q2 2021 Earnings Conference Call July 29, 2021 08:00 AM ET Company Participants Ingrid Goldberg - Vice President Finance & Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Uri Weinbe...
NovoCure (NASDAQ:NVCR) shares slide more than 4% premarket after the company posted second-quarter results that missed Wall Street estimates, hurt my a rise in research and development expenses during the period. Quarterly revenue rose 15% to $133.5M, but fell short of analysts' ave...
NovoCure (NASDAQ:NVCR): Q2 GAAP EPS of -$0.14 misses by $0.15. Revenue of $133.5M (+15.2% Y/Y) misses by $8.34M. Quarterly net revenues of $133.5 million, presenting 15% growth versus the second quarter of 2020 with 79% gross margin. There were 3,487 active patients at June 30, 2021, represen...
Quarterly net revenues of $133.5 million, presenting 15% growth versus the second quarter of 2020 with 79% gross margin Invested record $50 million in research and development initiatives across brain, thoracic and abdominal programs Novocure (NASDAQ: NVCR) today rep...
Awards totaling more than $2 million aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies Novocure (NASDAQ: NVCR) today announced the recipients of the 3rd Annual AACR-Novoc...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...